Dr. Jahanzeb on Eligibility Criteria for Immunotherapy Trials in NSCLC

Video

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.

Mohammad Jahanzeb, MD, professor of clinical medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non—small cell lung cancer (NSCLC).

There is a disconnect between patients enrolled in immunotherapy clinical trials versus the real-world setting in NSCLC, Jahanzeb notes. Due to the toxicity profile of immunotherapy, researchers are weary of upsetting an immune system that is fighting off other factors or comorbidities. Naturally, patients with autoimmune diseases or who have had organ or stem cell transplantation would be excluded from these studies.

Furthermore, certain subsets of lung cancer could have preexisting autoimmune mechanisms. If a patient has previously had pneumonitis and limited lung reserve, they would also likely miss enrollment criteria because they cannot afford to be in the 2% to 3% of patients who experience severe pneumonitis while on immunotherapy.

In terms of general criteria, researchers would avoid patients who have an additional invasive tumor besides NSCLC. Other exclusion factors include poor performance status, abnormal laboratory tests, and inadequate organ function. Jahanzeb concludes that these studies tend to have a bias against elderly patients, although a specific age is not put into the guidelines. Instead, these trials should consider physical age instead of numeric age.

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania